
Study
ID
HbA1c mean
difference (95% CI)
N, mean
(SD); Treatment
N, mean
(SD); Control
%
Weight
Long et at [46] 2012 -1.10 (-2.25, 0.05) 38, 8.7 (1.89) 39, 9.8 (3.11) 2.14
Walker et at [63] 2011 -0.46 (-0.94, 0.02) 228, 8.37 (1.89) 216, 8.83 (3.11) 12.12
Toobertet al [59] 2011 -0.60 (-1.43, 0.23) 113, 7.8 (3.19) 116, 8.4 (3.23) 4.07
Rosal et al [54] 2011 -0.52 (-1.15, 0.11) 124, 8.39 (1.89) 128, 8.91 (3.11) 7.02
Philis-Tsimikas [52] 2011 -0.10 (-0.69, 0.49) 64, 9 (1.7) 81, 9.1 (1.9) 8.16
Ruggiero et al [56] 2010 0.23 (-1.02, 1.48) 24, 8.73 (1.74) 18, 8.5 (2.25) 1.80
Davis et al [41] 2010 -0.40 (-1.38, 0.58) 85, 8.2 (3.69) 80, 8.6 (2.68) 2.93
Schillinger et al [57] 2009 -GMV group -0.30 (-0.86, 0.26) 101, 8.7 (1.9) 103, 9 (2.2) 8.85
Schillinger et al [57] 2009 -ATSM group 0.00 (-0.58, 0.58) 96, 9 (2) 103, 9 (2.2) 8.26
Babamoto et al [38] 2009 -0.20 (-1.25, 0.85) 56, 7.2 (1.89) 43, 7.4 (3.11) 2.54
Vincent et al [62] 2007 -0.70 (-1.66, 0.26) 9, 6.14 (.5) 8, 6.84 (1.3) 3.06
Lujan et al [47] 2007 -0.25 (-0.86, 0.36) 71, 7.76 (1.87) 70, 8.01 (1.8) 7.67
Anderson RM et al [29] 2005 0.21 (-0.31, 0.73) 117, 8.34 (1.91) 108, 8.13 (2.08) 10.28
Mayer-Davis et al [49] 2004 -Reimbursable intervention group 0.38 (-0.79, 1.54) 47, 8.86 (3.1) 56, 8.48 (2.9) 2.07
Mayer-Davis et al [49] 2004 -Intensive intervention group 0.16 (-0.87, 1.19) 49, 8.64 (2.5) 56, 8.48 (2.9) 2.64
Keyserling et al [45] 2002 -0.40 (-1.66, 0.86) 60, 11.1 (3.1) 58, 11.5 (3.81) 1.78
Brown et al [37] 2002 -0.75 (-1.46, -0.04) 112, 10.9 (2.56) 112, 11.6 (2.85) 5.59
Middelkoop et al [51] 2001 -1.10 (-2.04, -0.16) 53, 7.7 (1.89) 60, 8.8 (3.11) 3.20
Agurs-Collins et al [27] 1997 -1.60 (-3.47, 0.27) 30, 9.9 (2) 25, 11.5 (4.4) 0.81
Hawthorne et al [44] 1997 -0.34 (-1.09, 0.41) 106, 8.3 (1.89) 86, 8.64 (3.11) 5.01
Overall (I-squared = 0.0%, p = 0.515) -0.31 (-0.48, -0.14) 1583 1566 100.00
NOTE: Weights are from random effects analysis
-2
-1
0
1
Favors intervention
Favors control